drugset / Trial / NCT00615836

An Extension Study Investigating the Efficacy and Safety of a Fast-Dissolving ("Melt") Formulation of Desmopressin for the Treatment of Nocturia in Adults

NCT00615836

Phase 3 Completed 554 enrolled Ferring Pharmaceuticals
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study was to investigate the long term efficacy and safety of several doses of the Melt formulation of desmopressin in a broad population of adult patients with nocturia.

Timeline

Start
2007-12
Primary completion
2010-05
Completion
2010-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Desmopressin Peptide 10 ug Other
Subject Desmopressin Peptide 25 ug Other
Subject Desmopressin Peptide 50 ug Other
Subject Desmopressin Peptide 100 ug Other

Indications